Liposomal SunActive versus conventional iron for treatment of iron-deficiency anemia in children aged 2-12 years: a prospective randomized controlled trial.

BACKGROUND

Liposomal iron, a novel oral formulation of ferric pyrophosphate that demonstrates improved gastrointestinal absorption and bioavailability with fewer side effects than conventional iron, represents a significant advancement in the treatment of iron-deficiency anemia (IDA).

PURPOSE

To conduct an in-depth comparative study of liposomal SunActive and conventional iron supplements (iron polymaltose complex) for treating IDA in children aged 2-12 years.

METHODS

This prospective randomized controlled trial included 192 children who visited the outpatient clinic of the Pediatric Department at Menoufia University Hospital and were diagnosed with IDA. The patients were divided into group 1, 96 pediatric patients receiving oral liposomal SunActive iron; and group 2, 96 pediatric patients treated with conventional oral iron (iron polymaltose complex).

RESULTS

After 1 month of oral iron therapy, group 1 exhibited higher hemoglobin, hematocrit, serum ferritin, and serum iron levels and greater transferrin saturation than group 2. After 6 months of oral iron therapy, hemoglobin level (P<0.001), iron profile (P<0.001), and growth-related anthropometric measurements were higher in group 1 versus group 2 (P<0.001for z score for weight).

CONCLUSION

Iron supplements effectively improve anthropometric measurements, complete blood count parameters, and iron profiles. However, orally administered liposomal SunActive iron exhibits better effects, reduced drug refusal rates, and improved compliance rates, thereby benefiting children's growth.